

This section focuses on the ethical, legal, social, and policy questions arising from research involving human and animal subjects.

“Go Ask Alice”: The Case for Researching Schedule I Drugs

KENNETH V. ISERSON

Abstract: The available treatments for disorders affecting large segments of the population are often costly, complex, and only marginally effective, and many have numerous side effects. These disorders include dementias, debilitating neurological disorders, the multiple types of drug addiction, and the spectrum of mental health disorders.

Preliminary studies have shown that a variety of psychedelic and similar U.S. Drug Enforcement Administration Schedule I drugs may offer better treatment options than those that currently exist and pose potentially the same or even less risk than do legal psychoactive (alcohol, caffeine, nicotine) and nonpsychoactive (aspirin, acetaminophen, ibuprofen) substances. The pharmaceutical industry and academia, however, have largely avoided this avenue of research.

Fairness to the affected populations demands that these drugs be adequately studied and, if they or their congeners are shown to be effective, made available with the proper caveats, instructions, and protections that other potentially abused medications (e.g., narcotics) receive. These substances may prove to relieve patients’ struggles with less effective treatments and decrease mortality from nontreatment of some conditions.

Keywords: bioethics; pharmaceutical research; Schedule 1 drugs; drug and narcotic control; untreated/undertreated diseases

One pill makes you larger, and one pill makes you small
And the ones that mother gives you, don’t do anything at all
Go ask Alice, when she’s ten feet tall

(“White Rabbit,” sung by Jefferson Airplane, written by Grace Wing Slick)

Diseases without Good Treatments

As evidence continues to mount of an epidemic of opioid-related deaths in the United States, the entire world is plagued by addictions to multiple other drugs including ethanol, cocaine, amphetamines, and nicotine; the ever-present and increasing scourges of Alzheimer disease and other dementias; debilitating neurological disorders including Parkinson disease; and a multitude of mental health disorders.

Depression and anxiety, for example, are the world’s most common mental disorders. The World Health Organization estimates that, globally, the total number of people with depression exceeds 300 million. Depression is not only the single largest contributor to global disability (7.5% of all years lived with disability in 2015),

but it is also the major contributor to the nearly 800,000 suicides worldwide annually. It is most common in older adulthood (55 to 74 years), and women (7.5%) are more commonly affected than men (5.5%).¹ In the United States, almost 7% of adults suffer from at least one major depressive episode each year, and more than 19% suffer from anxiety disorders. Almost 13% of 12- to 17-year-old adolescents have had at least one major depressive episode, and almost one-third have had anxiety disorders in their lifetime. Severe impairment accompanied depressive episodes in about two-thirds of the individuals in both groups.²

Posttraumatic stress disorder (PTSD) affects about 3.6% of U.S. adults and 5% of 13- to 18-year-old adolescents annually.³ In the United States, 15.1 million adults ages 18 and older (6.2%) and more than 600,000 adolescents 12 to 17 years of age (2.5%) have *alcohol abuse disorder*. About 88,000 people per year die from alcohol-related causes, and alcohol-impaired driving fatalities account for about 10,000 annual deaths (31% of all driving fatalities).⁴ *Parkinson disease* affects about 1 million Americans, and approximately 60,000 new patients receive the diagnosis annually. More than 10 million people worldwide have the disease.⁵

Opioid addiction and overdoses have become epidemic in the United States. From July 2016 through September 2017, opioid overdoses increased 30% across 45 states, with a 70% increase in the Midwest and a 54% increase in large cities.⁶ *Cigarette smoking* is the single largest preventable cause of death and disease in the United States, killing more than 480,000 Americans each year. Nearly 29 million American adults smoke daily.⁷

Current Treatments

Currently, available treatments for these widespread disorders are often costly, complex, and only marginally effective, and many have numerous side effects—some of which are lethal. Studies, including those highlighted below (Table), have shown that a variety of psychedelic and similar U.S. Drug Enforcement Administration Schedule I drugs may offer better treatment options than those that currently exist. The large population affected by these disorders deserve to have regulatory barriers eased to permit a variety of robust studies that may point the way to new, more effective, and safer treatments—or even cures.

Relaxing regulations governing research on Schedule 1 drugs may also provide the opportunity to discover applications to medical conditions that investigators have overlooked. A well-known example is thalidomide, which was banned for causing severe birth defects (phocomelia) but was reintroduced when research showed that it was an immunomodulator and angiogenesis inhibitor effective for treating leprosy, multiple myeloma, and AIDS. Likewise, acetylsalicylic acid (aspirin) was used as an analgesic and anti-inflammatory drug for a century before its use as an antiplatelet agent and major treatment for acute myocardial infarctions became accepted practice.

If some of these drugs are approved for clinical practice, an entire new range of possibilities exist. Clinicians often use medications “off-label,” meaning that they use the drug for a purpose for which it has not been approved. According to the Federal Drug Administration, once a drug is approved, “healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient. . . [because] there might not be an approved drug to treat your disease or medical condition. . . [or] you may have

tried all approved treatments without seeing any benefits.”⁸ Some medications that are widely and successfully used “off-label” include sildenafil (Viagra[®]) for pulmonary arterial hypertension, amitriptyline for neurological pain and other disorders, methotrexate for multiple inflammatory disorders, and multiple cancer drugs that are used for cancers for which they have not been specifically approved.

Schedule 1 Drug Uses, Research, and Restrictions

In 1970, the United States enacted the Comprehensive Drug Abuse Prevention and Control Act.⁹ As of May 2018, the list contains 204 Schedule 1 drugs.¹⁰ In 1971, the United Nations also published a list of controlled drugs that was adopted by numerous countries. It now contains 26 Schedule I drugs.¹¹

Between 1950 and the mid-1960s, before U.S. and international government restrictions were enacted, psychiatric researchers trying to alleviate their patients’ disorders tested a variety of psychedelic drugs, most commonly psilocybin, lysergic acid diethylamide (LSD), and mescaline. Researchers worldwide published more than a thousand articles and several dozen books discussing their experience with about 40,000 patients. They also held 6 international conferences on psychedelic drug therapy.¹²

While early trials had suboptimal designs and small sample sizes, they tended to show that the tested medications helped those with substance abuse and neuroses, but not those with established psychoses.^{13,14} Early researchers who used LSD to treat alcohol abuse, for example, expected patients to experience a physiologically safe delirium, reasoning that most alcoholics stopped drinking after a bout of delirium tremens. While their therapy suggests at least short-term benefit, patients described a “mystical” or “mind manifesting” experience, leading to the term “psychedelic” from the Greek words *psychē* (ψυχή, “soul”) and *dēloun* (δῆλον, “to make visible, to reveal”), meaning “mind-revealing.”^{15,16} About this time, a German psychiatrist introduced the term “psycholytic” therapy, meaning the use of low (not psychedelic state-inducing) drug doses together with psychotherapy.¹⁷ For a short time, the therapy was legalized in Switzerland.¹⁸ Currently, but without psychiatric support, using microdoses of Schedule 1 drugs has become fashionable in some parts of the United States.¹⁹

The public fascination with psychedelic drugs used for recreational purposes has continued since the 1950s, with many millions of Americans experiencing the effects of LSD, psilocybin (mushrooms), mescaline, other hallucinogens, and MDMA (Ecstasy; 3,4-methylenedioxymethamphetamine), which shares features with psychedelic drugs.²⁰ Interestingly, they have been shown to be relatively safe—especially compared to alcohol and opiates.²¹

Following decades without substantive clinical research in psychedelics, a small but increasing number of human neuroimaging, psychology, and psychopharmacology studies have been published and shown promising results (Table 1). In addition, scientists and drug companies have overcome substantial barriers to obtain approval for clinicians to prescribe certain Schedule I drugs as medications for serious or unmet medical needs. One example is dronabinol (Marinol[®]; synthetic delta-9-THC in an oily capsule formulation), which was approved in 1985 for AIDS-related anorexia and later approved for chemotherapy-related nausea and vomiting. Others include gamma hydroxybutyrate (Xyrem[®]) in 2004 for narcolepsy

Table 1. Potential Clinical Uses for Selected Schedule 1 Drugs

Potential Clinical Use	Medication	Explanatory Notes	
Alcohol abuse disorder	LSD* ²³ Psilocybin ²⁴ Peyote ²⁵	LSD: meta-analysis of RCTs showed an OR of ~2 compared to placebo 1 month posttreatment. ²⁶ Few patients had side effects (generally nausea). ²⁷	Psilocybin (10 patients) side effects: 1 each vomiting, insomnia, diarrhea. ²⁸
Anxiety: cancer-related & end-of-life	Psilocybin ²⁹⁻³² LSD ³³		
Autism	LSD ³⁴	While multiple early autism-LSD studies were too flawed to be useful, more recent sophisticated research suggests that LSD may be useful.	
Cluster headaches	Psilocybin ^{35,36} LSD ³⁷	One study done with a nonpsychedelic LSD analogue ³⁸	
Cocaine/stimulant addiction	Mephedrone (bath salts)* ³⁹ Ibogaine ⁴⁰		
Depression: major/treatment-resistant & suicide	Psilocybin* ^{41,42} Ayahuasca ^{a,43} Psychedelics (any use decreased suicide risk) ⁴⁴	One dose; positive effects lasting for many months ⁴⁵	Ayahuasca: effective weeks to months, often with immediate vomiting.
Obsessive-compulsive disorder	Psilocybin ^{46,47}	Small study suggesting benefit	
Opioid addiction	Ibogaine ⁴⁸	Prolonged benefit after single administration	Deaths, often from QT prolongation or exacerbation of prior cardiac abnormalities. ⁴⁹
Parkinson disease	MDMA (Ecstasy)* ⁵⁰	Animal study	
Psychoses	LSD ⁵¹ Mescaline + LSD ⁵²⁻⁵⁴ Mescaline ^{55,56}	LSD alone with some improvement in psychoneurotic patients, not in schizophrenia	LSD + mescaline or mescaline alone generally with no improvement or worsening
Posttraumatic stress disorder	MDMA (Ecstasy) ⁵⁷	MDMA is not, strictly speaking, a classic psychedelic, but is a Schedule 1 substance. ⁵⁸	
Tobacco/nicotine dependence	Psilocybin ⁵⁹	With CBT. Small study, but 67% abstinence at 12 months. ⁶⁰	Felt fear of being trapped.

Continued

Table 1. Continued

	Other Possible Uses
Anti-inflammatory	All tested psychedelics, no matter their structural class, demonstrate anti-inflammatory activity about as potent as steroids. One drug, (R)-DOI, is extraordinarily potent and “may be an effective therapy for asthma, atherosclerosis, coronary artery disease, and inflammatory bowel disease.” ⁶¹
Glaucoma	Multiple animal studies suggest that some psychedelics reduce intraocular pressure. ⁶²
Tissue regeneration	Animal studies suggest that some psychedelics help regenerate damaged or transplanted tissues. ⁶³
Cognitive enhancement	Mescaline and LSD may improve creative problem solving. ⁶⁴

Abbreviations: CBT, cognitive behavioral therapy; LSD, lysergic acid diethylamide; MDMA, 3,4-methylenedioxymethamphetamine (Ecstasy); RCT, randomized clinical trials; (R)-DOI, 2,5-dimethoxy-4-iodoamphetamine.

* Studies suggest a positive effect.

^a Plant-based decoction containing *N,N*-dimethyltryptamine (DMT).

and the cannabis-derived nabiximol (Sativex[®]; delta-9-tetrahydrocannabinol and cannabidiol) for spasticity, which is approved in Canada and Europe and under review for approval in the United States.²²

Getting U.S. Food and Drug Administration permission to develop and conduct clinical trials on psychedelic and related drugs requires not only overcoming significant political hurdles, but also targeting serious or unmet medical needs. That is the direction in which current researchers are heading. Yet designing scientifically acceptable studies may prove difficult.

Issues Complicating Research

While the pharmaceutical industry and academia routinely investigate new drug classes to address diseases with inadequate or unmet treatments, they have avoided researching most Schedule 1 drugs, especially the psychedelics. This is due to several factors, including the difficulty of obtaining samples, potentially negative publicity, financial issues (funding for academia and marketing difficulties and a potential lack of patent protection for companies), and potential negative repercussions from a large-scale diversion of marketed drugs for recreational purposes, as now occurs with opioids, stimulants, benzodiazepines and Z-drugs. Another hurdle they face is obtaining institutional review board (IRB) approval for any studies.

IRBs review any clinical trials on humans, and their criteria is based on well-known ethical codes and regulations (Nuremberg Code [1947], Declaration of Helsinki [2000], Belmont Report [1979], Council for International Organizations of Medical Sciences Guidelines [2002], U.S. Common Rule [1991]). Their principle requirements are that the research (1) must have social and clinical value and be sufficiently important to justify any risk or inconvenience to study subjects, (2) be scientifically valid, and (3) encompass subjects that are informed of and, whenever possible, protected from foreseeable risks.

Research Ethics

Social and Clinical Value

The value of studying a potentially useful group of drugs seems obvious. The medical conditions listed in the Table currently have inadequate treatments or unmet needs. Far from “orphan” or rare diseases, these conditions plague large portions of the U.S. and world populations. The extensive prior human research provides suggestive evidence for the efficacy of selected Schedule 1 drugs, particularly psychedelics, for these conditions.

Scientifically Valid

To ethically study a new drug, researchers must define a target disease or symptom, understand its natural history and pathophysiology, and preferably know the drug’s mechanism of action. Then they must design scientifically valid and feasible studies that reliably show whether the drug is both safe and effective at different doses.⁶⁵ Although researchers understand the diseases and some of the pathophysiology they are targeting, fulfilling the other research elements may be problematic.

Although chemical drug activity is known, the mechanism for any psychedelic’s therapeutic effect has yet to be discovered. That is not unusual for some new medications, but researchers still need to elucidate a dose-response relationship; duration of action; and toxicity, efficacy and safety at the levels used.⁶⁶ This may be complicated by the process of legally obtaining (or needing to manufacture) the drugs with techniques and chemical compositions that meet regulatory standards.

Finally, and perhaps most difficult, is the need for double-blind studies, which provide reliable endpoints and meaningful outcome assessments. Blinding of psychedelic drugs is extremely difficult, since the drugs’ subjective effects are so evident. Moreover, for psychiatric conditions, such as depression or obsessive-compulsive disorder, outcome measures can be subjective. Historical trials with these drugs generally had too few patients, often used subjective reported outcomes, and provided too few details to be replicated. More recent trials have attempted to overcome these limitations, and validated improvement measures now exist for most of the entities that need to be initially tested.

Protection from Foreseeable Risks

IRBs and researchers are obligated to minimize, as much as possible, any physical, psychological, economic, or social risks and to maximize the benefits associated with the study.⁶⁷ Unlike most tested drugs, many of the Schedule 1 compounds have been used extensively by large populations for extensive recreational and religious experiences over past decades, if not centuries. Their relatively good safety record suggests that any risks associated with many of the conditions being considered for treatment may far outweigh any harms associated with these drugs.⁶⁸ Those using most of these drugs (ibogaine is the exception) seemed to experience as few or fewer adverse consequences than those using the most commonly used legal psychoactive (alcohol, caffeine, nicotine) and nonpsychoactive (aspirin, acetaminophen, ibuprofen) substances. In fact, one might wonder, given the extensive experience with some of these agents, if it would be reasonable to

begin most trials at Phase I or even Phase 2. Of course, the study participant populations will need to be carefully selected and the studies carefully monitored so that if the medication proves ineffective or has unreasonable side effects, the study can be terminated early.⁶⁹

Conclusions/Recommendations

A variety of diseases lack effective prevention, treatment, or cure. We must ask ourselves as a society if we are actively working to ameliorate or cure these disorders or are obstructing valuable research avenues. Limited studies suggest that many may benefit from the use of currently restricted Schedule I (illegal) drugs.

In most cases, experience shows that these drugs pose little or even much less risk than do legal psychoactive (alcohol, caffeine, nicotine) and non-psychoactive (aspirin, acetaminophen, ibuprofen) substances. We need adequate scientific studies that can demonstrate their efficacy for specific conditions. At present, legal, financial, and scientific barriers (i.e., limited knowledge of diseases and objective outcomes) prevent adequate exploration of these potentially useful modalities.

In cases where Schedule I drugs are better than the available alternatives, or for those instances where no alternatives exist, fairness to the population demands that the Schedule I drugs be adequately studied and, if they or their congeners are shown to be effective, made available, with the proper caveats, instructions, and protections that other potentially abused prescribed medications (e.g., narcotics) receive.

The current situation harms both individual patients and society. Without permission and funding to study important groups of drugs, patients not only lack possible interventions for serious ailments but also must grapple with less effective treatments with serious side effects and increased mortality from nontreatment of some conditions; society at large, meanwhile, wastes resources on drug enforcement and forgoes potential tax revenue from legalization. It's time that we have the courage to "ask Alice" what medical benefits lie on the other side of the psychedelic door.

Notes

1. World Health Organization. *Depression and Other Common Mental Disorders: Global Health Estimates*. Geneva: World Health Organization; 2017.
2. National Institute of Mental Health. *Statistics*; available at <https://www.nimh.nih.gov/health/statistics/index.shtml> (last accessed 4 May 2018).
3. National Institute on Alcohol Abuse and Alcoholism. *Alcohol Facts and Statistics*; available at <https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-facts-and-statistics> (last accessed 4 May 2018).
4. See note 3, National Institute on Alcohol Abuse and Alcoholism.
5. Parkinson's Foundation. *Statistics*; available at <http://parkinson.org/Understanding-Parkinsons/Causes-and-Statistics/Statistics> (last accessed 4 May 2018).
6. National Institute for Drug Abuse. *Opioid Overdose Crisis*; available at <https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis> (last accessed 4 May 2018).
7. Centers for Disease Control and Prevention. *Burden of Tobacco Use in the U.S.*; available at <https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html> (last accessed 4 May 2018).
8. Food and Drug Administration. *Understanding Unapproved Use of Approved Drugs "Off Label"*; available at <https://www.fda.gov/ForPatients/Other/OffLabel/ucm20041767.htm> (last accessed 12 April 2018).

9. Comprehensive Drug Abuse Prevention and Control Act. Pub.L. 91–513, 84 Stat.1236, enacted October 27, 1970.
10. U.S. Department of Justice, Drug Enforcement Agency. *Controlled Substance Schedules*; available at <https://www.deadiversion.usdoj.gov/schedules/#define> (last accessed 6 May 2018).
11. *United Nations Convention on Psychotropic Substances*; 1971; available at https://www.unodc.org/pdf/convention_1971_en.pdf (last accessed 6 May 2018).
12. Grinspoon L, Bakalar JB. *Psychedelic Drugs Reconsidered*. New York: Basic Books; 1979:221–3.
13. Rucker JJ, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs: Past, present & future. *Neuropharmacology*; forthcoming.
14. Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drug: Past, present, and future. *Neuropsychopharmacology* 2017 Apr 26;42(11):1–9.
15. Chwelos N, Blewett DB, Smith CM, Hoffer A. Use of d-lysergic acid diethylamide in the treatment of alcoholism. *Quarterly Journal of Studies on Alcohol* 1959;20:577–90.
16. See note 14, Carhart-Harris, Goodwin 2017:1–9.
17. Leuner HA. Basic functions involved in the psychotherapeutic effect of psychotomimetics. *Research in Psychotherapy*. Washington DC: American Psychological Association; 1968:466–70.
18. Sessa B. Is there a case for MDMA-assisted psychotherapy in the UK? *Journal of Psychopharmacology* 2007 Mar;21(2):220–4.
19. Gregoire C. *Everything You Wanted to Know About Microdosing (But Were Afraid to Ask)*; 2017 Jan 24; available at https://www.huffingtonpost.com/entry/psychedelic-microdosing-research_us_569525afe4b09dbb4bac9db8 (last accessed 6 May 2018).
20. See note 12, Grinspoon, Bakalar 1979:221–3.
21. See note 14, Carhart-Harris, Goodwin 2017:1–9.
22. Ibid.
23. Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. *Journal of Psychopharmacology* 2012;26(7):994–1002.
24. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. *Journal of Psychopharmacology* 2015 Mar;29(3):289–99.
25. Albaugh BJ, Anderson PO. Peyote in the treatment of alcoholism among American Indians. *American Journal of Psychiatry* 1974;131:1247–50.
26. See note 23, Krebs, Johansen 2012:994–1002.
27. See note 13, Rucker JJ, Iliff J, Nutt DJ (forthcoming).
28. See note 24, Bogenschutz, Forcehimes, Pommy, Wilcox, Barbosa, Strassman, 2015:289–99.
29. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Archives of General Psychiatry* 2011;68(1):71–8.
30. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of Psychopharmacology* 2016 Dec;30(12):1181–97.
31. Ross S, Bossis A, Guss J, Agin-Lieb G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *Journal of Psychopharmacology* 2016 Dec;30(12):1165–80.
32. Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. *Neurotherapeutics* 2017 Jul 1;14(3):734–40.
33. Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. *Journal of Nervous and Mental Disease* 2014 Jul;202(7):513.
34. Murphy DG, Daly E, Schmitz N, Toal F, Murphy K, Curran S, et al. Cortical serotonin 5-HT_{2A} receptor binding and social communication in adults with Asperger’s syndrome: An in vivo SPECT study. *American Journal of Psychiatry* 2006;163:934–6.
35. Sewell RA, Halpern JH, Pope HG. Response of cluster headache to psilocybin and LSD. *Neurology* 2006;66:1920–2.
36. Karst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series. *Cephalalgia* 2010;30:1140–4.
37. See note 36, Karst, Halpern, Bernateck, Passie, 2010:1140–4.

38. Bird S. Mephedrone and cocaine: Clues from Army testing. *Straight Statistics*; 2011; available at <http://straightstatistics.fullfact.org/article/mephedrone-and-cocaine-clues-army-testing> (last accessed 5 May 2018).
39. Schenberg EE, De Castro Comis MA, Chaves BR, Da Silveira DX. Treating drug dependence with the aid of ibogaine: A retrospective study. *Journal of Psychopharmacology* 2014;28:993–1000.
40. Carhart-Harris RL, Bolstridge M, Day CM, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. *Psychopharmacology* 2018 Feb 1;235(2):399–408.
41. Osório FD, Sanches RF, Macedo LR, dos Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. *Revista Brasileira de Psiquiatria*. 2015 Mar;37(1):13–20.
42. Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. *J Clin Psychopharmacol* 2016 Feb 1;36(1):77–81.
43. Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. *Journal of Psychopharmacology* 2015 Mar;29(3):280–8.
44. Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. *Lancet Psychiatry* 2016 Jul 1;3(7):619–27.
45. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *Journal of Clinical Psychiatry* 2006 Nov 11;67(11):1735–40.
46. Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. *American Journal of Drug and Alcohol Abuse*. 2018 Jan 2;44(1):24–36.
47. Malcolm BJ, Polanco M, Barsuglia JP. Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. *Journal of Psychoactive Drugs* 2018 Apr 1:1–10.
48. Litjens RP, Brunt TM. How toxic is ibogaine? *Clinical Toxicology* 2016 Apr 20;54(4):297–302.
49. Huot P, Johnson TH, Lewis KD, Koprach JB, Reyes MG, Fox SH, et al. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers *in vitro* and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. *Journal of Neuroscience* 2011;31:7190–8.
50. Busch AK, Johnson WC. L.S.D. 25 as an aid in psychotherapy: Preliminary report of a new drug. *Diseases of the Nervous System* 1950;11(8):241–3.
51. Hoch PH, Cattell JP, Pennes HH. Effects of mescaline and lysergic acid (d-LSD-25). *American Journal of Psychiatry* 1952 Feb;108(8):579–84.
52. Denber HCB, Merlis S. Studies on mescaline I: Action in schizophrenic patients. *Psychiatric Quarterly* 1955;29:421–9.
53. Pennes HH. Clinical reactions of schizophrenics to sodium amytal, pervitin hydrochloride, mescaline sulfate, and d-lysergic acid diethylamide (LSD25). *Journal of Nervous and Mental Disease* 1954;119(2):95–112.
54. Merlis S. The effects of mescaline sulfate in chronic schizophrenia. *Journal of Nervous and Mental Disease* 1957 Jul 1;125(3):432–3.
55. Bedi G, Luan Phan K, Angstadt M, de Wit H. Effects of MDMA on sociability and neural response to social threat and social reward. *Psychopharmacology (Berl.)* 2009;207:73–83.
56. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. *Journal of Psychopharmacology* 2013;27(1):28–39.
57. Nichols DE. Psychedelics. *Pharmacology Review* 2016 Apr 1;68(2):264–355.
58. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. *American Journal of Drug and Alcohol Abuse* 2017;43:55–60.
59. See note 58, Johnson, Garcia-Romeu, Griffiths, 2017:55–60.
60. Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: An emerging new paradigm. *Clinical Pharmacology & Therapeutics* 2017 Feb 1;101(2):209–19.
61. See note 57, Nichols, 2016:264–355.
62. See note 57, Nichols, 2016:264–355.
63. See note 57, Nichols, 2016:264–355.

Research Ethics

64. Harman WW, McKim RH, Mogar RE, Fadiman J, Stolaroff MJ. Psychedelic agents in creative problem-solving: A pilot study. *Psychology Reports* 1966 Aug;19(1):211–27.
65. Krippner S. Psychedelic drugs and creativity. *Journal of Psychoactive Drugs* 1985 Oct 1; 17(4):235–46.
66. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? *JAMA* 2000; 283(20):2701–11.
67. Sellers EM, Leiderman DB. Psychedelic drugs as therapeutics: No illusions about the challenges. *Clinical Pharmacology and Therapeutics* 2018 Apr 1;103(4):561–4.
68. See note 65, Emanuel, Wendler, Grady, 2000:2701–11.
69. See note 14, Carhart-Harris, Goodwin 2017:1–9.